• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Third party research

Probi: Managing costs well in Q3 - ABG

Probi

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Miss on Q3 sales (-12%) and EBITDA (-10%) vs ABGSCe
China faced headwinds due to macroeconomic factors
EBITDA revised down by 2-3% for '24e-'26e


Encouraging B2C sales efforts in the Nordics

Probi reported a soft Q3'24 with sales amounting to SEK 143.7m (-12% vs. ABGSCe of SEK 162.4m). The gross margin increased to 34.2% (vs. ABGSCe at 33.2%) as a result of strong cost control throughout the business. Looking at the Americas, Probi highlights the weak overall demand for probiotics in the US, and sales amounted to SEK 106.3m (-8% y-o-y, -11% vs. ABGSCe). APAC continues to be sluggish, particularly in China, which has been negatively impacted by macroeconomic factors and high inventory levels. In Q3, APAC sales were SEK 10.1m (-22% y-o-y, -22% vs. ABGSCe). EMEA was flat y-o-y with sales of SEK 27.3m (-10% vs. ABGSCe), with B2B sales developing positively. Probi has introduced new branding for B2C in the Nordics, which resulted in some out phasing in Q3. However, management emphasises that this has been well-received and efforts will continue in Q4.